Getting to the core of fibrosis: Targeting redox imbalance in aging

Annals of Translational Medicine

Volumn 4, Issue 5, 2016, Pages

  Hecker, Louise ^a,b   Thannickal, Victor J ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLOROPHENYL) 4 [3 (DIMETHYLAMINO)PHENYL] 5 METHYL 1H PYRAZOLO[4,3 C]PYRIDINE 3,6(2H,5H) DIONE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4;

AGING; BIOACCUMULATION; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE PREDISPOSITION; DNA DAMAGE; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; EDITORIAL; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; LIFE EXPECTANCY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; REDOX IMBALANCE; RISK FACTOR; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 85006219560     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.21037/atm.2015.12.45     Document Type: Editorial

References (45)

1. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-92.
2. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-82.
3. Rangarajan S, Kurundkar A, Kurundkar D, et al. Novel Mechanisms for the Anti-Fibrotic Action of Nintedanib. Am J Respir Cell Mol Biol 2016;54:51-9.
4. Mehal WZ, Iredale J, Friedman SL. Scraping fibrosis: expressway to the core of fibrosis. Nat Med 2011;17:552-3.
5. Liepelt A, Tacke F. Healing the scars of life-targeting redox imbalance in fibrotic disorders of the elderly. Ann Transl Med 2015;3:S13.
6. Harman D. Aging: overview. Ann N Y Acad Sci 2001;928:1-21.
7. Gagliano N, Grizzi F, Annoni G. Mechanisms of aging and liver functions. Dig Dis 2007;25:118-23.
8. Gagliano N, Arosio B, Santambrogio D, et al. Agedependent expression of fibrosis-related genes and collagen deposition in rat kidney cortex. J Gerontol A Biol Sci Med Sci 2000;55:B365-72.
9. Glaser J, Stienecker K. Pancreas and aging: a study using ultrasonography. Gerontology 2000;46:93-6.
10. Calabresi C, Arosio B, Galimberti L, et al. Natural aging, expression of fibrosis-related genes and collagen deposition in rat lung. Exp Gerontol 2007;42:1003-11.
11. Fell CD, Martinez FJ, Liu LX, et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010;181:832-7.
12. Hecker L, Thannickal VJ. Nonresolving fibrotic disorders: idiopathic pulmonary fibrosis as a paradigm of impaired tissue regeneration. Am J Med Sci 2011;341:431-4.
13. Collard HR. The age of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010;181:771-2.
14. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810-6.
15. Hecker L, Logsdon NJ, Kurundkar D, et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci Transl Med 2014;6:231ra47.
16. Thannickal VJ. Mechanistic links between aging and lung fibrosis. Biogerontology 2013;14:609-15.
17. Kuwano K, Nakashima N, Inoshima I, et al. Oxidative stress in lung epithelial cells from patients with idiopathic interstitial pneumonias. Eur Respir J 2003;21:232-40.
18. Kuwano K, Kunitake R, Kawasaki M, et al. P21Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1996;154:477-83.
19. Nanthakumar CB, Hatley RJ, Lemma S, et al. Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nat Rev Drug Discov 2015;14:693-720.
20. Thannickal VJ, Zhou Y, Gaggar A, et al. Fibrosis: ultimate and proximate causes. J Clin Invest 2014;124:4673-7.
21. Buffenstein R, Edrey YH, Yang T, et al. The oxidative stress theory of aging: embattled or invincible? Insights from non-traditional model organisms. Age (Dordr) 2008;30:99-109.
22. Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A 2008;105:13051-6.
23. Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008;178:729-37.
24. Thannickal VJ, Loyd JE. Idiopathic pulmonary fibrosis: a disorder of lung regeneration? Am J Respir Crit Care Med 2008;178:663-5.
25. Kinnula VL, Fattman CL, Tan RJ, et al. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005;172:417-22.
26. Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2093-101.
27. Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000;279:L1005-28.
28. Thannickal VJ. Oxygen in the evolution of complex life and the price we pay. Am J Respir Cell Mol Biol 2009;40:507-10.
29. Lambeth JD. Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med 2007;43:332-47.
30. Thannickal VJ. Aging, antagonistic pleiotropy and fibrotic disease. Int J Biochem Cell Biol 2010;42:1398-400.
31. Bernard K, Hecker L, Luckhardt TR, et al. NADPH oxidases in lung health and disease. Antioxid Redox Signal 2014;20:2838-53.
32. Aoyama T, Paik YH, Watanabe S, et al. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology 2012;56:2316-27.
33. Sancho P, Mainez J, Crosas-Molist E, et al. NADPH oxidase NOX4 mediates stellate cell activation and hepatocyte cell death during liver fibrosis development. PLoS One 2012;7:e45285.
34. Bettaieb A, Jiang JX, Sasaki Y, et al. Hepatocyte Nicotinamide Adenine Dinucleotide Phosphate Reduced Oxidase 4 Regulates Stress Signaling, Fibrosis, and Insulin Sensitivity During Development of Steatohepatitis in Mice. Gastroenterology 2015;149:468-80.e10.
35. Spadoni T, Svegliati Baroni S, Amico D, et al. A reactive oxygen species-mediated loop maintains increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis. Arthritis Rheumatol 2015;67:1611-22.
36. Barnes JL, Gorin Y. Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases. Kidney Int 2011;79:944-56.
37. Sedeek M, Callera G, Montezano A, et al. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am J Physiol Renal Physiol 2010;299:F1348-58.
38. Kuroda J, Ago T, Matsushima S, et al. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci U S A 2010;107:15565-70.
39. Ago T, Matsushima S, Kuroda J, et al. The NADPH oxidase Nox4 and aging in the heart. Aging (Albany NY) 2010;2:1012-6.
40. Griffith B, Pendyala S, Hecker L, et al. NOX enzymes and pulmonary disease. Antioxid Redox Signal 2009;11:2505-16.
41. Hecker L, Vittal R, Jones T, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009;15:1077-81.
42. Bray N. Lung disease: resetting the redox balance in lung fibrosis. Nat Rev Drug Discov 2014;13:415.
43. Harrison C. Fibrotic disease: A pair of novel targets. Nat Rev Drug Discov 2009;8:773.
44. Laleu B, Gaggini F, Orchard M, et al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem 2010;53:7715-30.
45. Cross AR, Segal AW. The NADPH oxidase of professional phagocytes-prototype of the NOX electron transport chain systems. Biochim Biophys Acta 2004;1657:1-22.